5.4 Medium
CVSS3
Attack Vector
NETWORK
Attack Complexity
LOW
Privileges Required
LOW
User Interaction
REQUIRED
Scope
CHANGED
Confidentiality Impact
LOW
Integrity Impact
LOW
Availability Impact
NONE
CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:C/C:L/I:L/A:N
6 Medium
AI Score
Confidence
High
3.5 Low
CVSS2
Access Vector
NETWORK
Access Complexity
MEDIUM
Authentication
SINGLE
Confidentiality Impact
NONE
Integrity Impact
PARTIAL
Availability Impact
NONE
AV:N/AC:M/Au:S/C:N/I:P/A:N
0.001 Low
EPSS
Percentile
28.2%
Successful exploitation of these vulnerabilities could allow an attacker to modify communications between downstream devices or cause some features of the affected devices to become disabled.
The following versions of Innokas Yhtymä Oy Vital Signs Monitors are affected:
A stored cross-site scripting (XSS) vulnerability exists in the affected products that allow an attacker to inject arbitrary web script or HTML via the filename parameter to multiple update endpoints of the administrative web interface.
CVE-2020-27262 has been assigned to this vulnerability. A CVSS v3 base score of 4.6 has been calculated; the CVSS vector string is (AV:N/AC:L/PR:L/UI:R/S:U/C:L/I:L/A:N).
HL7 v2.x injection vulnerabilities exist in the affected products that allow physically proximate attackers with a connected barcode reader to inject HL7 v2.x segments into specific HL7 v2.x messages via multiple expected parameters.
CVE-2020-27260 has been assigned to this vulnerability. A CVSS v3 base score of 5.3 has been calculated; the CVSS vector string is (AV:P/AC:L/PR:N/UI:N/S:C/C:N/I:H/A:N).
Julian Suleder, Nils Emmerich, and Birk Kauer of ERNW Research GmbH; and Dr. Oliver Matula of ERNW Enno Rey Netzwerke GmbH reported these vulnerabilities to the Federal Office for Information Security (BSI), Germany, in the context of the BSI project ManiMed (Manipulation of medical devices).
Innokas Yhtymä Oy recommends users update to the latest Version 1.7.15b or later. Software Version 1.7.15b mitigates reported vulnerabilities. Additionally, the following mitigations are available:
CISA recommends users take defensive measures to minimize the risk of exploitation of this vulnerability. Specifically, users should:
CISA reminds organizations to perform proper impact analysis and risk assessment prior to deploying defensive measures.
CISA also provides a section for control systems security recommended practices on the ICS webpage on us-cert.cisa.gov. Several recommended practices are available for reading and download, including Improving Industrial Control Systems Cybersecurity with Defense-in-Depth Strategies.
Additional mitigation guidance and recommended practices are publicly available on the ICS webpage on us-cert.cisa.gov in the Technical Information Paper, ICS-TIP-12-146-01B–Targeted Cyber Intrusion Detection and Mitigation Strategies.
Organizations observing any suspected malicious activity should follow their established internal procedures and report their findings to CISA for tracking and correlation against other incidents.
No known public exploits specifically target these vulnerabilities.
web.nvd.nist.gov/view/vuln/detail?vulnId=CVE-2020-27260
web.nvd.nist.gov/view/vuln/detail?vulnId=CVE-2020-27262
cwe.mitre.org/data/definitions/74.html
cwe.mitre.org/data/definitions/79.html
public.govdelivery.com/accounts/USDHSCISA/subscriber/new?topic_id=USDHSCISA_138
twitter.com/CISAgov
twitter.com/intent/tweet?text=Innokas%20Yhtym%C3%A4%20Oy%20Vital%20Signs%20Monitor+https://www.cisa.gov/news-events/ics-medical-advisories/icsma-21-007-01
us-cert.cisa.gov/ics
us-cert.cisa.gov/ics
us-cert.cisa.gov/ics/alerts/ICS-ALERT-10-301-01
us-cert.cisa.gov/ics/recommended-practices
us-cert.cisa.gov/ics/tips/ICS-TIP-12-146-01B
us-cert.cisa.gov/sites/default/files/recommended_practices/NCCIC_ICS-CERT_Defense_in_Depth_2016_S508C.pdf
www.dhs.gov
www.dhs.gov/foia
www.dhs.gov/performance-financial-reports
www.facebook.com/CISA
www.facebook.com/sharer/sharer.php?u=https://www.cisa.gov/news-events/ics-medical-advisories/icsma-21-007-01&title=Innokas%20Yhtym%C3%A4%20Oy%20Vital%20Signs%20Monitor
www.first.org/cvss/calculator/3.0#CVSS:3.0/AV:N/AC:L/PR:L/UI:R/S:U/C:L/I:L/A:N
www.first.org/cvss/calculator/3.0#CVSS:3.0/AV:P/AC:L/PR:N/UI:N/S:C/C:N/I:H/A:N
www.instagram.com/cisagov
www.linkedin.com/company/cybersecurity-and-infrastructure-security-agency
www.linkedin.com/sharing/share-offsite/?url=https://www.cisa.gov/news-events/ics-medical-advisories/icsma-21-007-01
www.oig.dhs.gov/
www.surveymonkey.com/r/CISA-cyber-survey?product=https://www.cisa.gov/news-events/ics-medical-advisories/icsma-21-007-01
www.usa.gov/
www.whitehouse.gov/
www.youtube.com/@cisagov
mailto:?subject=Innokas%20Yhtym%C3%A4%20Oy%20Vital%20Signs%20Monitor&body=www.cisa.gov/news-events/ics-medical-advisories/icsma-21-007-01
5.4 Medium
CVSS3
Attack Vector
NETWORK
Attack Complexity
LOW
Privileges Required
LOW
User Interaction
REQUIRED
Scope
CHANGED
Confidentiality Impact
LOW
Integrity Impact
LOW
Availability Impact
NONE
CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:C/C:L/I:L/A:N
6 Medium
AI Score
Confidence
High
3.5 Low
CVSS2
Access Vector
NETWORK
Access Complexity
MEDIUM
Authentication
SINGLE
Confidentiality Impact
NONE
Integrity Impact
PARTIAL
Availability Impact
NONE
AV:N/AC:M/Au:S/C:N/I:P/A:N
0.001 Low
EPSS
Percentile
28.2%